Relatório de estágio em coordenação de ensaios clínicos na Blueclinical, LTD by Sousa, Joana Cristina Mendes Cruz de
  
Universidade de Aveiro 
2016  
Departamento de Ciências Médicas 
JOANA CRISTINA 
MENDES CRUZ DE 
SOUSA 
 
TRAINING  REPORT IN CLINICAL TRIALS 
COORDINATION AT BLUECLINICAL, LTD 
 
RELATÓRIO DE ESTÁGIO EM COORDENAÇÃO DE 
ENSAIOS CLÍNICOS NA BLUECLINICAL, LTD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
Universidade de Aveiro 
2016 
Departamento de Ciências Médicas 
JOANA CRISTINA 
MENDES CRUZ DE 
SOUSA 
 
 
TRAINING  REPORT IN CLINICAL TRIALS 
COORDINATION AT BLUECLINICAL, LTD 
 
RELATÓRIO DE ESTÁGIO EM COORDENAÇÃO DE 
ENSAIOS CLÍNICOS NA BLUECLINICAL, LTD 
 
 
 
Relatório de estágio curricular apresentado à Universidade de Aveiro para 
cumprimento dos requisitos necessários à obtenção do grau de Mestre em 
Biomedicina Farmacêutica, realizado sob a orientação científica do Professor 
Doutor Bruno Miguel Alves Fernandes do Gago, Professor Auxiliar Convidado 
do Departamento de Ciências Médicas da Universidade de Aveiro e da Dra.
Lucília Penteado, Clinical Research Manager na Blueclinical Ltd. 
 
  
  
  
  
  
 
 
  
 
 
 
“The capacity to learn is a gift; 
The ability to learn is a skill; 
The willingness to learn is a choice.”  
                                                                     Brian Herbert 
 
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
o júri 
 
presidente Professor Doutor Nelson Fernando Pacheco da Rocha 
professor catedrático da Universidade de Aveiro 
  
arguente Professora Doutora Alexandra Isabel Cardador de Queirós 
professora coordenadora s/agregação da Universidade de Aveiro 
  
orientador Professor Doutor Bruno Miguel Alves Fernandes do Gago 
professor auxiliar convidado do Departamento de Ciências Médicas da Universidade de Aveiro 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
 
  
  
 
 
  
 
agradecimentos 
 
Ao Professor Luís Almeida e ao Professor Bruno Gago, responsáveis pelo 
Mestrado em Biomedicina Farmacêutica, pela orientação e pelos 
conhecimentos transmitidos durante estes dois anos.  
Ao Professor Luís Almeida, ao Professor Sérgio Simões e à Dra.Cristina 
Lopes, pela oportunidade de realizar o meu estágio curricular na Blueclinical.  
Ao Professor Bruno Gago e à Dra. Lucília Penteado, pela pronta 
disponibilidade, orientação e revisão deste relatório.  
A toda a equipa da Blueclinical, em especial à Vanessa Valente, por me terem 
acolhido. 
A todos os meus amigos, sem exceção, agradeço a amizade e o incentivo.  
Aos meus colegas de mestrado, pelos momentos de entusiasmo e 
aprendizagem partilhados em conjunto.  
A todos os departamentos do Centro Hospitalar de Vila Nova de Gaia/Espinho 
com os quais colaborei. 
Aos meus pais, sem os quais não teria sido possível concretizar esta etapa da 
minha vida.  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
palavras-chave 
 
investigação clínica,  coordenação de ensaios clínicos, ensaios clínicos, 
estudos observacionais, centro de investigação, Biomedicina Farmacêutica, 
Blueclinical 
   
resumo 
 
 
Este relatório descreve as atividades desenvolvidas como coordenadora de 
ensaios clínicos no âmbito do estágio curricular do Mestrado em Biomedicina 
Farmacêutica, lecionado na Universidade de Aveiro.  
O estágio curricular decorreu no Centro Hospitalar de Vila Nova de 
Gaia/Espinho, no período compreendido entre 15 de setembro de 2015 e 15 
de abril de 2016.  
O relatório encontra-se estruturado em sete capítulos, sendo que no segundo
capítulo são mencionados os objetivos do estágio, procedendo-se no capítulo 
seguinte à caracterização das instituições acolhedoras. Posteriormente, no 
capítulo quatro é apresentado o estado de arte do processo de investigação e 
desenvolvimento farmacêutico, incluindo a caraterização da situação atual dos 
ensaios clínicos em Portugal. As atividades realizadas no âmbito da 
coordenação de ensaios clínicos estão descritas no capítulo cinco. Nos últimos 
capítulos, analisa-se e procede-se à avaliação do estágio, sendo também 
mencionadas as estratégias adotadas para solucionar os problemas e 
dificuldades que foram surgindo.  
Em suma, considero que o estágio curricular cumpriu a sua finalidade, ao 
possibilitar a aquisição de competências como coordenadora de investigação 
clínica.  
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This report describes the activities performed as clinical research coordinator, 
during the internship of the Master in Pharmaceutical Medicine, at the 
University of Aveiro.   
The curricular internship took place at Blueclinical – particularly at Centro 
Hospitalar de Vila Nova de Gaia/Espinho, from 15th September 2015 to 15th
April 2016. 
The report is divided into seven chapters. The training objectives are presented 
in the two chapter, and in the next chapter the host institutions are 
characterized. Then, in the four chapter it is presented the state-of-the-art of 
the pharmaceutical research and development process, including the current
situation of the clinical trials in Portugal. The activities carried out under the 
scope of the clinical trials coordination are described in five four. In the last 
chapters, it is performed a critical analysis and the assessment of the 
internship, and are also mentioned the strategies adopted in order to solve the 
problems and difficulties that arose. 
In conclusion, I consider that the internship fulfilled its purpose, providing the 
acquisition of skills as clinical research coordinator.  
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1. INTRODUCTION 
The present report describes the activities performed as Clinical Research Coordinator 
(CRC), in the scope of the internship of the Master in Pharmaceutical Medicine, at 
University of Aveiro.   
This curricular internship was developed at Blueclinical – particularly at Centro Hospitalar 
de Vila Nova de Gaia/Espinho (CHVNG/E), from 15th September 2015 to 15th April 2016. 
The activities were performed under supervision of Dra.Lucília Penteado, Clinical 
Research Manager at Blueclinical. 
The internship is a key part of the academic path to complement the teaching-learning 
process. This practical experience allowed me to apply and to consolidate the scientific 
and theoretical knowledge learned during the Master. Moreover, it also allowed me to 
acquire and to develop competences/skills in professional environment as CRC. 
Nowadays, the role of CRC has been a growing importance considering the increase of 
complexity of the clinical trials and the tighter regulatory requirements. Furthermore, CRC 
is a link between the research subjects, the investigator and other site team members. 
CRC has a vital role at site to the execution of a successful clinical trial. 
In this report, I will describe my work experience in the field of clinical research.   
This report is divided into seven chapters, which comprises a) the identification of my 
training objectives and personal goals (chapter 2), b) the presentation of the host 
institutions, namely the history, the vision and the organisation (chapter 3) and c) the state 
of the art of the Pharmaceutical Research and Development process and the current 
situation of the clinical trials in Portugal (chapter 4). In the chapter 4, I also considered 
relevant to include an overview of the regulatory framework. The activities carried out 
during the internship are described in chapter 5, and in the subchapter 5.2, the specific 
activities performed as CRC are explained, since the beginning of a new trial or study to 
the closeout of the trial. In the last chapters 6 and 7, I will analyse my internship 
experience and I will discuss the outcomes of this trainee.    
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2. TRAINING OBJECTIVES 
The internship was planned in order to achieve the following objectives:  
 to develop skills as CRC;  
 to identify the working procedures at clinical research site;  
 to contribute to the improvement of the clinical research at CHVNG/E;  
 to acquire knowledge of pathological aspects and treatment guidelines of several 
diseases; 
 to apply learned concepts and skills to a practical setting; 
 to recognise the multidisciplinary framework of the activities developed in the 
scope of the clinical research coordination;   
 to manage time effectively;  
 to improve communication and problem solving skills on-the-job training;  
 to establish networking with peers, investigators and others professionals and 
institutions; 
 personal and professional development. 
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3. OVERVIEW OF THE HOST INSTITUTION AND PARTNER 
HOSPITAL 
This chapter presents a description of the host institution Blueclinical - Investigação e 
Desenvolvimento em Saúde, Ltd., its structure, activities and its role in promoting clinical 
research. Although, Blueclinical - Investigação e Desenvolvimento em Saúde, Ltd 
henceforth referred to as Blueclinical, was the host institution of my internship, my 
activities as CRC were performed at CHVNG/E. Therefore, I consider that it is also 
relevant to mention this institution in this chapter.  
 
3.1. BLUECLINICAL  
Blueclinical is a translational medicine company that was founded in May 2012 and is 
headquartered at Avenida Villagarcia de Arosa, Matosinhos – Porto. The aim of this 
company is to bring the projects of institutions, startups and established companies to 
clinical practice (1). To achieve this purpose, Blueclinical’s activity is organized into three 
business units: Research and Development (R&D), Phase I and Clinical Research 
Partnership (CRP), which cover all the different phases of the drug discovery process (1). 
The public organogram outlines the internal structure of Blueclinical (figure 1). 
 
BLUECLINICAL R&D 
The mission of Blueclinical R&D is to establish partnerships with institutions and 
companies in the development of successful translational medicine projects (2). This 
business unit intends translating basic research findings into investigation in humans, and 
finally, into medical care (2). Blueclinical R&D unit provides a unique expertise and 
experience, namely in the definition of the development and the business plans. Their 
consulting services include:  
a. preparing and implementing preclinical, clinical and regulatory plans for new 
medicines medical devices and other health products; 
b. the definition of the target product profile and the definition of preclinical and 
regulatory plans; 
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c. preparing and supporting the process of obtaining scientific and regulatory advice 
from competent regulatory authorities;  
d. placing and monitoring preclinical studies;  
e. preparing the investigator’s brochure and investigational medicinal product (IMP) 
dossier; 
f. preparing and submitting the clinical trial application to the competent authorities 
and ethics authorities; 
g. planning, conduction and reporting clinical pharmacology clinical trials (Phase I) in 
healthy subjects or patients; ´ 
h. planning, implementing, monitoring and reporting therapeutic clinical trials (Phase 
II to IV) or observational studies with medicines or medical devices (2). 
Furthermore, Blueclinical R&D has interest into to participate in international consortia 
candidate to Horizon 2020 calls or to other funding agencies (2).  
 
BLUECLINICAL PHASE I 
Blueclinical Phase I is a clinical research unit, whose mission are conducted effective 
studies in healthy subjects and early stage studies in selected patients populations. This 
unit was founded on 12th July 2013. Its facilities are located at Hospital da Prelada, in 
Porto, with large benefits that include its location with easy accesses, an efficient logistic 
service and an accredited clinical laboratory. Phase I unit has modern, safety and comfort 
facilities, with 34 beds (3).   
Phase I unit has a clinical and scientific team with long experience in diverse types of 
studies for the global market, both generics and innovative medicines, such as: 
a. bioavailability/bioequivalence studies, to determine the similarity of different 
formulations of the same medicine, according to the requirements of the European 
Medicine Agency (EMA), Food and Drug Administration (FDA) and other 
regulatory authorities;  
b. Phase I studies with innovative medicines; 
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c. drug-drug interactions studies;  
d. food interactions trials to evaluate if medicines must be taken along with food or 
out of meals;  
e. dosage form proportionality studies;  
f. entry-into-Man trials;  
g. studies with special populations (3).  
All studies are conducted in compliance with international regulatory and ethical 
standards, after approval from the competent authorities, the National Ethics Committee 
for Clinical Research (Comissão de Ética para a Investigação Clínica – CEIC) and the 
National Committee of Data Protection (Comissão de Nacional de Proteção de Dados - 
CNPD).   
Volunteers with an interest in participating in the above-mentioned trials can apply to 
Phase I email. Then, they are contacted by phone and inquired if they are interested and 
have availability to perform a screening visit, considering the trials that will be performed 
at Phase I facilities.  
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Figure 1 Public Blueclinical’s organogram 
ARS-N Administração Regional de Saúde do Norte; CHBV Centro Hospitalar do Baixo Vouga, E.P.E.; CHCB Centro 
Hospitalar da Cova da Beira, E.P.E.; CHL Centro Hospitalar de Leiria, E.P.E.; CHTMAD Centro Hospitalar de Trás-os-
Montes e Alto Douro, E.P.E.; CHVNGE Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.; CRM Clinical Research 
Management; CRP Clinical Research Partnership; HGO Hospital Garcia de Orta, E.P.E.; HSOG Hospital Senhora da 
Oliveira Guimarães, E.P.E.;  PV Pharmacovigilance; ULSAM Unidade Local de Saúde do Alto Minho, E.P.E.; ULSM 
Unidade Local de Saúde de Matosinhos, E.P.E..  
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BLUECLINICAL CRP 
The mission of Blueclinical CRP is to support the activity of clinical research centres, 
promoting mutual growth, efficiency and excellence in clinical research. Blueclinical CRP 
is a network of hospitals and primary care centres. Approximately 5 million of the 
Portuguese population has access to these institutions (4).   
The main reasons of the lack of the efficiency of clinical research are related with 
administrative or organizational factors. Thus, Blueclinical CRP through the creation of 
highly motivated and organized teams and efficient structure intends to deliver excellence 
in clinical research (4).  
The research activity at the clinical sites supported by Blueclinical CRP is guided by three 
key principles: quality, training and support. The quality management system of this 
business unit assures that all clinical research activities are documented and performed 
through a standardized process. This management system pretends to maximize the 
efficiency of the processes and to assure full compliance with the legal and ethical 
requirements. Furthermore, training and qualification of each clinical research team 
member are stimulated and supported by CRCs at each centre (4). 
CRCs provided by Blueclinical CRP are skilled, specialized and motivated professionals. 
They are committed to support the development of clinical research of high efficiency and 
quality, and to comply with all ethical and legal requirements (4).  
Currently, Blueclinical CRP has partnership agreements contracts with the Administração 
Regional de Saúde do Norte, which comprehends the primary care units and nine 
hospitals, with different localizations. The following hospitals are supported by Blueclinical 
CRP in clinical research activities:  
 Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E; 
 Centro Hospitalar de Trás-os-Montes e Alto Douro, E.P.E; 
 Centro Senhora de Oliveira, E.P.E; 
 Centro Hospitalar do Baixo Vouga, E.P.E; 
 Centro Hospitalar da Cova da Beira, E.P.E; 
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 Centro Hospitalar de Leiria, E.P.E; 
 Hospital Garcia da Orta, E.P.E; 
 Unidade Local de Saúde do Alto Minho, E.P.E;  
 Unidade Local de Saúde de Matosinhos, E.P.E.   
At each centre, the Administration Board (AB) designates a physician to coordinate the 
clinical research office.   
 
3.2. CENTRO HOSPITALAR DE VILA NOVA DE GAIA/ESPINHO 
CHVNG/E is a referenced centre of the north of the country. It offers a large range of 
healthcare services such as: a) a polyvalent emergency department for all age group, b) a 
medical and surgery care, c) a continuing care and a rehabilitation service, and also d) an 
ambulatory medical care of several medical specialties. Overall, CHVNG/E provides a 
wide range of health care services to 700 000 inhabitants, covering a geographic area that 
includes Vila Nova de Gaia, Espinho and Entre Douro e Vouga councils. It is also 
considered reference centre to all councils located at north of the country, above Vouga 
River (5). 
This centre is divided in 3 units: a) unit I, previously known as Hospital Eduardo Santos 
Silva, located at Rua Conceição Fernandes, s/n – Vila Nova de Gaia; b) unit II, previously 
known as Hospital Distrital de Gaia, whose facilities are located at Rua Francisco Sá 
Carneiro, s/n – Vila Nova de Gaia; c) unit III, the old one Hospital Nossa Senhora da 
Ajuda, located at Rua 37, s/n – Espinho (6).  
The clinical research office, designated as Gabinete de Investigação Clínica (GIC) is 
located at unit I, where it also located the main part of above-mentioned medical care 
services and the emergency room. In the hospital organization chart, GIC is integrated in 
the training, education and research department (figure 2) (7).  
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Gabinete de Investigação Clínica (GIC) 
 CRC 
Training, education and research Clinical Research 
Management  
back office 
Figure 2 CRCs within Blueclinical’s and CHVNG/E’s organization 
The CRCs integrate the Blueclinical CRP business unit, which is supervised by the Clinical Research Management. 
The back office gives supports to GIC. In the CHVNG/E’s structure, CRCs are part of the support office of GIC. 
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4. STATE-OF-THE-ART  
This chapter is intended to give an overview of the Pharmaceutical R&D process and the 
current situation of the clinical research, including the situation of the clinical trials in 
Portugal. Moreover, it is described the regulatory framework of the clinical trials.  
 
4.1. CLINICAL RESEARCH 
Clinical research plays a vital part in making progress towards better knowledge, 
understanding of human health and disease and the development of new, safe and 
effective treatments (8). The Regulation European Union (EU) No.536/2014 of the 
European Parliament and of the Council of 16 April 2014 on Clinical Trials on medicinal 
products for human use, replacing the decade-old Directive 2001/20/EC – the Clinical 
Trials Directive, states that a clinical study means any investigation in relation to human 
intended:  
a) to discover or verify the clinical, pharmacological or other pharmacodynamic effects of 
one or more medicinal products;  
b) to identify any adverse reactions to one or more medicinal products; or 
c) to study the absorption, distribution, metabolism and excretion of one or more 
medicinal products (9). 
Two different categories of research can be established: clinical trials (using an IMPs, 
medical devices or can also include surgical, physical or psychotherapeutic procedures) 
and non-interventional trials (8).  
Clinical trial means a clinical study which fulfils any of the following conditions:  
a) the assignment of the subject to a particular therapeutic strategy is decided in advance 
and does not fall within normal clinical practice;  
b) the decision to prescribe the IMPs is taken with the decision to include the subject in 
the clinical study; or 
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c) diagnostic or monitoring procedures in addition to normal clinical practice are applied to 
the subjects (9).  
In contrast to clinical trial, non-interventional studies are described as: “a study in the 
context of which knowledge from the treatment of persons with drugs in accordance with 
the instructions for use specified in their registration in analysed using epidemiological 
methods" (10, 11). These types of studies may be prospective and/or retrospective. In a 
prospective study, the investigator follows the impact of the exposure going forward in 
time and wait for the outcome of interest (13). In contrast, retrospective studies are 
conducted after the development of the outcomes of interest (10, 11). 
Besides providing greater knowledge about the safety and effectiveness of treatment 
regimens with respect to the local standards of clinical care, non-interventional studies 
can also map risks in the real world (12). They are usually performed during phase IV of 
drug development.   
 
4.2. BIO/PHARMACEUTICAL R&D PROCESS 
Pharmaceutical R&D is defined as the process of discovering and introducing new drug 
products in the market (13).  
Pharmaceutical and biotechnology companies are struggling to bring new molecular and 
biologic entities through R&D and to generate attractive returns on investment (14). 
Despite the number of new molecular and biologic entities in the R&D pipeline has been 
rising 7% annually, the average cost for pharmaceutical companies to bring a new 
molecular entity (NME) to market is also rising rapidly. The costs are now estimated to be 
approximately US$1.8 billion (14, 15). Therefore, R&D productivity has been declining 
over the years. The overall cohort internal rate of return has declined, from 10.1 per cent 
in 2010 to 5.5 per cent in 2014, but in 2014 for the first time, there has been a halt to the 
decline and even an upflit in R&D returns relative to 2013 (14-16). Several factors has 
contributed to make the pharmaceutical industry’s survival, at least in its current form, 
threatened, but the following stand out: a) a reduced R&D output in the form of 
successfully launched truly innovative NMEs, b) a diminishing market exclusivity for 
recently launched new medicines and c) the lost due to patent expirations for successful 
products (14, 15). Additionally, a range of environment issues also contributes to the 
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pressure under pharmaceutical industry, such as an increasingly cost-constrained 
healthcare systems and a more demanding regulatory requirements (15). The attrition rate 
remains high in drug development process, due the number of efficacy- and safety-related 
failures during clinical trials (15, 17). The main reasons to the failure during clinical trials 
are the lack of efficacy (25%), the clinical safety concerns (12%) and the toxicological 
findings in pre-clinical evaluation (20%) (18).  
Regarding the long development timelines, despite the implementation of a wide variety of 
new practices and technologies intended to accelerate clinical development cycle times, 
the opposite has occurred (14). In 2010, the average clinical phase duration was 6.8 
years, increasing 15% during the preceding decade (14).  
Therefore, the R&D operating model, which served the drug development enterprise well 
during the past 50 years, is obsolete and no longer viable (14). New models of 
collaboration, including open innovation platforms, the integration of big data systems that 
leverage structured and unstructured electronic health information, modification of legacy 
processes, the adoption of adaptive clinical trial designs and more patient centric clinical 
trials, are all emerging approaches that hold promise in transforming R&D process and 
performance (14).  
Besides that, two international initiatives, “Critical Path Initiative” (CPT) and “Innovative 
Medicines Initiative” (IMI) were developed to improve drug development and promote 
better medicines (18-20).    
The purposes of CPT, developed by FDA in United States of America, are to increase 
efficiency and productivity of the R&D process, to create an innovative science and to 
reduce uncertainty, applying new scientific tools (19). The list identifies 76 tangible 
examples where new scientific discoveries – in fields such as genomics, imaging and 
informatics (the analysis of biological information using computers and statistical 
techniques) – can be applied during product development to improve the accuracy of tests 
that predict the safety and efficacy of potential medical products (21).  This initiative 
outlined specific areas of Critical Path focus, including:  
a. developing better evaluation tools such as biomarkers and new assays;  
b. streamlining clinical trials by modernizing the clinical trial sciences to make trials safe 
and efficient;  
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c. harnessing bioinformatics (e.g. move from a paper-based to electronic environment for 
exchanging information and overseeing the safety of FDA-regulated products); 
d. moving manufacturing into the 21st century using tools such as process analytic 
technology and nanotechnology; 
e. developing products to address urgent public health needs, including improved 
antimicrobial testing, new animal models to test bioterrorism countermeasures and 
vaccine testing; 
f. focusing on at-risk populations, such as paediatrics (19, 21). 
The IMI is a public-private partnership developed by European Commission and the 
European Federation of Pharmaceutical Industries and Associations that aims to boost 
the development of new medicines by implementing new collaborative endeavours 
between biopharmaceutical companies, regulators, academy and patients (22). This 
initiative has 4 pillars: a) improvement the predictivity of drug safety evaluation, b) 
improvement the predictivity of efficacy evaluation, c) knowledge management through 
more information and data utilization and d) promotion of education to resolve training 
gaps (20, 22).  There is already an IMI 2 initiative, developed to deliver the right treatment 
to the right patient at the right time for priority diseases, supporting the personalised 
medicine and prevention (20). 
 
4.3. DRUG DEVELOPMENT PROCESS 
The drug development process is typically divided into three major steps: discovery, 
preclinical development and clinical trials (23). Once a potential therapeutic drug or 
biologic has been discovered, the process of developing the therapeutic for a particular 
disease, begins with the preclinical development (24). This process encompasses the 
activities that link drug discovery in the laboratory to initiation of human clinical trials. 
Preclinical studies can be designed to a) identify a lead candidate from several hits;                 
b) develop the best procedure for new drug scale-up; c) select the best formulation;                  
d) determine the route, frequency, and duration of exposure; and e) ultimately support the 
intended clinical trial design (23). The transition from discovery to preclinical development 
is a continuum process, and results of preliminary pharmacology and toxicology testing 
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often contribute to lead drug candidate selection (23). It is estimated that 5000 to 10000 
compounds are screened during the pre-discovery and discovery phases. Most of those 
compounds are eliminated, and about 250 are selected for the preclinical phase. To the 
preclinical tests, in average only 5 IMPs are selected and submitted as an investigational 
new drug (20). This application to regulatory authorities is mandatory before initiate 
clinical trials (23). 
The clinical trials process of a study drug is conventionally divided into four phases, as 
described below:  
a. phase I (human pharmacology) - these studies represent the first in-human 
exposure to the drug, and involve a small number of subjects, usually healthy non-patient 
volunteers (20-80). In some circumstances, the subjects involved are patients, e.g. with 
anticancer therapeutics. The phase I trials are designed to determine the metabolic and 
pharmacologic profiles of the agent in humans, to identify possible side effects, and, if 
possible, to gain evidence of drug effectiveness.  Phase I studies are typically single blind-
studies, and they are intended to minimize potential risk to future exposition, providing 
sufficient information to enable the design of scientifically valid phase II studies (25). 
b. phase II (therapeutic exploratory) - controlled clinical studies are performed to 
evaluate the effectiveness of the drug in a specific disease, and to define an effectiveness 
dose that provides the optimal benefit-risk profile. These studies typically involve several 
hundred patients (25).  
c. phase III (therapeutic confirmatory) - are performed large-scale clinical studies, 
involving several thousand patients. The main purpose of these studies is to confirm the 
effectiveness and safety findings from previous studies (25). 
d. phase IV (therapeutic use) – the aim of these trials is to provide additional 
information regarding the product’s safety, efficacy, or manufacturing processes. They are 
conducted after marketing approval (25).  
After the completion of clinical trials process – until phase III, all data obtained from 
manufacturing, preclinical and clinical studies are summarized, and the sponsor submits 
the request for marketing authorisation (25).  
The process of drug development is expensive and time-consuming. An alternative 
development paradigm referred to as “quick win, fast fail” paradigm of drug development 
is proposed as a specific strategic to improve industry R&D productivity (15). In this new 
paradigm, the technical uncertainty is intentionally decreased before the expensive later 
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development stages (Phase II and Phase III) through the establishment of proof-of-
concept (POC) (15). POC clinical trials are carefully designed to establish the safety of 
drug candidates in the target population and explore the relationship between the dose 
and desired activity, as either measured directly or by means of a surrogate endpoint (26).  
In “quick win, fast fail” paradigm of drug development (figure 3), a reduced number of new 
molecular entities entering Phase II and Phase III advance with a higher probability of 
technical success. Any savings gained from this paradigm can be reinvested to further 
enhance R&D productivity (15). 
 
Figure 3 The traditional drug development model (part a) and an alternative, the quick-win, fast-fail 
model (part b).   
CS candidate selection; FED first efficacy dose; FHD first human dose; PD product decision; 
Adapated from (15). 
 
4.4. CLINICAL TRIALS IN PORTUGAL 
Clinical trials are considered a keystone for economy, providing early access to innovative 
medicines to patients (27).  
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In Portugal, between 2006 and 2012, the number of submission of clinical trials to 
Autoridade Nacional do Medicamento e Produtos de Saúde (INFARMED) decreased 
26%, from 160 to 118 studies. In 2011, while Europe experienced a small average market 
growth of 2.6%, only 88 studies were submitted. However, during 2012, there was a slight 
and progressive recovery (27). Regarding of submission request to clinical trials in 
Portugal, between 2013-2014, there was a growth of +11.1% and between 2014-2015, a 
growth of 10.8%. The number of authorized of clinical trials have also been growing, with 
123 clinical trials authorized in 2015, when compared with only 99 in 2012. This increase 
occurs along with a decrease in the time of decision by competent authorities (28) (figure 
4).  
The analysis by phases of development shows that the majority of clinical trials performed 
in 2015 are Phase III studies and antineoplastic drugs and immunomodulators continued 
to be the therapeutic classes more studied (figures 5 and 6). This scenario not changed 
significantly since 2005. Moreover, it is interesting to highlight that, between 2012-2015, 
there was an outstanding increase from 3 to 15 Phase I studies, respectively (figure 5). 
However, the rate of clinical trials/million habitants in Portugal stills among the lowest of 
the Western Europe (28).  
In 2013, PwC published a report about clinical trials in Portugal, which describes specific 
challenges of clinical trials conduction. The above-mentioned increase in Phase I-IV 
clinical trials has a relevant impact on Portuguese economy. For the clinical trials area, 
this gain is €1.98, which means that every €1 investment generated in clinical trials activity 
provides a return of €1.98 for the general Portuguese economy. This study estimates that 
the activity of clinical trials in Portugal had the potential to improve to as high as €143 
million in 2015, if a series of current obstacles were overcome (27).  
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Requests for clinical trial authorisation 
submitted authrorised rejected average time for authorisation 
Figure 4 The number of requests for clinical trial authorisation 
Adapated from  Statistics of Clinical Trials  between 2006 – 2015 http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_CLINICOS/ESTATISTICAS 
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The development of clinical trials in Portugal faces several barriers such as: a) the lack of 
recognition of the strategic importance of the clinical investigation to improve of health 
care and to contribute to the national economy; b) limitations of organizational, 
infrastructural and regulatory aspects; c) negative connotation of clinical trials; d) the low 
performance in recruiting patients (enrolment) by the clinical investigators; e) little 
competitive approval deadlines (27).  
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Figure 5 % clinical trial authorisation applications submitted to INFARMED, divided by clinical 
development phases 
Adapated from  Statistics of Clinical Trials  between 2006 – 2015 
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In Portugal, the lack of information of the clinical trials to the patients is considered one 
cause for the poor recruitment rates (27). Portuguese legislation restricts other sources of 
recruitment, such as mass media strategies via newspaper or radio advertisement (29). 
 
 
 
 
 
 
Figure 6 Classification of experimental drugs by therapeutic areas  
Adapated from  Statistics of Clinical Trials  between 2006 – 2015 
http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_CLINICOS/ESTATIST
ICAS 
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Then, the main source of recruitment is through the medical practice and medical 
references from professional colleagues (29). However, the “Plataforma Nacional de 
Ensaios Clínicos” was created to allow that the information about clinical trials stays more 
accessible (30).  
The PwC report also proposes strategies to support the clinical trials in Portugal, such as 
the development of an independent organisation dedicated to clinical research, a national 
health education and clinical trials disclosure strategy, and the inclusion of clinical 
research in professional careers (27).  
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5. ON THE JOB TRAINING 
5.1. GENERIC TRAINING 
This sub-chapter outlines the generic training performed in different fields, which provided 
the basic knowledge and skills for study coordination activities. In the following sections, it 
will be mentioned the Good Clinical Practice (GCP) training, the Dangerous Goods 
training, and it will also be presented an overview of the clinical trials regulatory 
framework. Moreover, the training in electronic data capture and interactive response 
systems will be presented, as well, due their relevance to the conduction of the trial.  
 
5.1.1. GOOD CLINICAL PRACTICE  
GCP is an international ethical and scientific quality standard for designing, conducting, 
recording and reporting trials that involve the participation of human subjects. Compliance 
with the GCP provides public assurance that the rights, safety and well-being of trial 
subjects are protected, consistent with the principles that have their origin in the 
Declaration of Helsinki. It also ensures that the clinical trial data are credible (31). This 
course is performed online, and it is mandatory to integrate the research team, as study 
coordinator. The GCP training must be completed at a minimum of every 3 years.  
 
5.1.2. DANGEROUS GOODS TRAINING 
This training is mandatory for the preparation and shipment of dangerous goods, including 
for the shipping of category A substances, infectious substance affecting humans, 
category B substances and biological substances. The online course presents the 
regulations imposed on most laboratories and highlights their importance, classifies the 
infectious substance for transport, demonstrates the procedures for legally and safely 
shipping of various infectious specimens and integrates dangerous goods procedures into 
laboratory. At the end, there is a self-assessment quiz to obtain the certification. This 
certification is valid for two years (32).    
 
 22 
 
5.1.3. CLINICAL TRIALS REGULATORY FRAMEWORK  
The clinical investigation is a highly regulated area, as set out in several guidelines, 
regulations and directives, as mentioned below.  
The Declaration of Helsinki, a statement of ethical principles for medical research 
involving human subjects, including research on identifiable human material and data, 
was developed by The World Medical Association (33). The first version was adopted on 
June 1964, and then, several revisions and two clarifications were made.  
The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) is a project involving regulatory authorities of 
Europe, Japan and USA and experts from the pharmaceutical industry. The guidelines 
from ICH are divided into four topics in order to facilitate the search of a specific guidance: 
Safety, Quality, Efficacy and Multidisciplinary. The main purpose is to achieve global 
harmonization, but these guidelines are not mandatory (34). The ICH GCP guideline 
E6(R1) was published in 1996, and describes the responsibilities and expectation from the 
main involved parties (investigators, Clinical Research Associates (CRAs), sponsors and 
Ethics Committees) in clinical trial conduction. It is an international standard to ensure the 
compliance with GCP for designing, conducting, recording and reporting trials involving 
humans (35). Current, it was voted the adoption of an addendum to guideline for ICH GCP 
E6(R1). This addendum (E6(R2)) aims to encourage sponsors to implement improved 
oversight and management of clinical trials, while continuing to ensure protection of 
human subjects participating in trials.  
In the EU, all clinical trials performed need to be conducted in accordance with the Clinical 
trials Directive 2001/20/CE, until the implementation of the new  Clinical Trials Regulation 
EU no.536/2014, that was adopted on 16 June 2014 (it is expected to be in force by 
October 2018). The Directive 2001/20/CE was elaborated in order to approximate laws, 
regulations and administrative provisions of all Member States (MSs), related to the 
implementation of good clinical practice in the conduction of clinical trials on medical 
products for human use (36). However, it has often been criticized as having excessive 
bureaucracy, and it did not achieve its goals because it was implemented differently in 
MSs. This Directive was transposed to Portuguese legislation to law no.46/2004 of 19th 
August, which was repealed by law no. 21/2014, of 16th April, and this last one was 
changed by law no.73/2015, of 27th July (37).  
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The new regulation no.536/2014 will ensure that the rules for conducting clinical trials are 
identical throughout the EU, namely the assessment of applications for clinical trials, 
which is divided in two parts. Part I is jointly assessed by all MSs concerned. Part II is 
assessed by each MS concerned separately. Besides this, the purpose of the regulation is 
improving timelines and flexibility, increasing transparency and supporting more 
information to the citizens of Europe. Overall, this regulation intends to eliminate the 
current obstacles in the current directive (38).   
The EU Clinical Trials Regulation has also taken up certain requirements from two others 
relevant Directives:  
 Commission Directive 2005/28/EC, of 8th April 2005 – sets out principles and detailed 
guidelines for GCP as regards IMPs for human use, as well as the requirements for 
authorisation of the manufacturing or importation of such products;  
 Commission Directive 2003/94/EC, of 8th October 2003 – defines the principles and 
guidelines of Good Manufacturing Practice in respect of medicinal products and 
investigational for human use (38). 
Portuguese law no.102/2007, of 2nd April is a transposition into internal legal order of 
Directive no.2005/28/EC. Besides the above-mentioned national legislation, it is also 
relevant to consider the national law no.67/98 of 26th October about personal data 
protection, a transposition of Directive no.95/46/CE of 24th October 1995 (39).  
 
5.1.4. ELECTRONIC DATA CAPTURE SYSTEMS  
In clinical trials, there are different systems adopted by pharmaceutical companies and 
Clinical Research Organization (CRO) to collect clinical data in electronic format – the 
electronic Case Report Form (eCRF). The different systems, such as Medidata Rave®, 
InformTM, Oracle® and DataTrackTM, require online training and an assessment quiz. 
These trainings gave me the skills to use them in an efficient way, namely reporting the 
patient’s data with accuracy.   
 
 
 24 
 
5.1.5. INTERACTIVE RESPONSE SYSTEMS 
Interactive Voice/Web Response System (IVRS/IWRS) helps in handling the logistical 
issues related to the conduction of clinical trials. IVRS implies the use of telephone, and 
provides automated confirmation of assignments by fax. On the other hand, the 
transaction in the IWRS is performed in an online system, and the confirmation report is 
sent by e-email or fax. 
The web-based system is the most used, due the accessible anytime through an internet 
connection. This system allows the drug supply management, the patient enrolment and 
randomization and the dispensation of the study drug. When applicable, it is also 
performed in the system the registration of an unscheduled visit, the discontinuation of the 
treatment or an unblinding procedure. Screening failures are also registered in the 
IWRS/IWRS system. There are different examples of IVR/IWR systems, such as 
ClinPhone®, Almac® and EndpointClinical®.  
 
5.2. SPECIFIC TRAINING 
The aim of this sub-chapter is to describe the activities performed in the scope of clinical 
trial coordination, integrated in a broader description of the related processes of a clinical 
study. Additionally, it will also be summarised in which clinical trials and observational 
studies I was involved, and what type of tasks and activities were performed in each 
study.  The activities that I performed during the training are described in table 1.  
The clinical trial coordination activities will be presented through the perspective of a 
clinical research centre, according to the stage of implementation and conduction of a 
clinical study. This process can be divided into: initiation, conduction and close out 
activities.  
 
5.2.1. CLINICAL TRIAL INITIATION ACTIVITIES 
The initiation process of a clinical trial at site includes a wide range of activities and 
processes namely: a) the signature of a confidential agreement; b) the completion of the 
feasibility questionnaire; c) the qualification visit; d) the preparation of submission  
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Table  1 The activities performed as CRC during the training.  
 Study visits Other activities 
 
ICF Screening Randomisation Treatment End of 
Treatment 
Submission 
phase 
eCRF Monitoring 
visit 
Documents 
management 
Sample 
shipment 
ONCOLOGY  
SELECT-1    x x  x x x x 
INCYTE    x x  x x x x 
FLAURA x x x x x  x x x x 
MO29750 x x x x   x x x x 
MK3475-091      x  x x  
BI 1302.5      x  x x  
M12-914 x x x x   x x x x 
HEMATOLOGY  
CHRONOS-3 x x      x x  
B3281006 x x      x x x 
IMAN         x x  
GASTROENTEROLOGY           
MLN0002-3026      x   x  
CT-P13      x   x  
NEPHROLOGY           
Dolomites x x x x   x x x x 
OPHTHALMOLOGY           
SALT x x x x   x x x x 
INTERNAL MEDICINE           
NAVIGATE x x x x   x x x  
Carmelina    x     x x 
GPD0101 x x     x   x 
DERMATHOLOGY           
Optimise x x x x  x x x x x 
PNEUMOLOGY           
Dynagito    x x    x x 
Estair x x  x   x  x x 
Arietta      x   x  
REUMATOLOGY           
CT-P10 3.2  x   x x      
DS5565-A-E310 x x x x x      
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documents and the analysis of the financial contracts; e) the clinical trial approval; f) the 
investigator meeting; f) the clinical trial initiation visit.  
 
FEASIBILITY QUESTIONNAIRE  
First of all, after a new proposal to a new study is received, it is necessary to identify who 
is/are the physician(s) from the site that can have interest in the study.  This new proposal 
can be received from three different sources, such as: a) directly by the sponsor; b) 
through the CRO to which the sponsor delegates the responsibility for selecting the 
suitable sites; c) from the Blueclinical’s back-office. In some cases, the sponsor or the 
CRO contacts directly the physician. The above-mentioned proposal is sent with a brief 
summary of the study and with the confidentiality agreement. This agreement is signed by 
the Principal Investigator (PI), in order to ensure the confidentiality of the process. Only 
after this, it is sent more information regarding the study, namely the protocol synopsis 
and the feasibility questionnaire to the interested physician. This feasibility questionnaire 
is an assessment tool to determine the site’s conditions to perform the study. Moreover, it 
is also required information concerning the standard of care, the patients’ recruitment 
potential, the infrastructures and the facilities of the site, and also the human and material 
resources available. After the feasibility questionnaire has been answered, it is necessary 
wait until to receive information regarding the selection of the clinical research site (40).  
QUALIFICATION VISIT 
When the clinical research site is selected to be one of the possible sites to conduct the 
clinical study, the CRA or other element from the sponsor or CRO representative requires 
the schedule of a qualification visit. All departments involved in order to fulfil the protocol 
requirements should be present, e.g. the Pharmacy, the department of Clinical Pathology, 
the department of Anatomy Pathology and the department of Imagiology, if applicable. 
The qualification visit is performed to a) assess if the site’s interest in the clinical trial 
remains; b) review the site adequacy to perform the study and the access to target 
population; c) inquire the training and experience of the study staff. Moreover, during this 
meeting, it is also presented the study objectives, the protocol-required procedures and is 
discussed with the investigators the inclusion and exclusion criteria (41). Regarding the 
observational studies, the qualification visit is usually performed by phone, between the 
CRA and the PI. 
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SUBMISSION PHASE 
After the qualification visit, it is necessary to wait until receive the feedback about 
selection. If the site is selected to participate in the trial, the submission process is initiated 
with the preparation of the required documents. These documents are mandatory to 
obtain approval of a clinical trial from all competent authorities (CEIC, INFARMED and 
CNPD) in Portugal (figure 7). The negotiation of the financial contract for submission to 
the AB of the hospital is performed by Blueclinical’s back-office.  
During the submission phase to the competent authorities and to AB of CHVNG/E, the 
following documents are mandatory:   
a. authorisation submission letter – is elaborated by the sponsor or sponsor´s 
representative, and asks permission to conduct the clinical trial at CHVNG/E. It is also 
presented a summary of the study.  
b. sponsor statement – this letter presents the status of approval of the trial by the 
competent authorities INFARMED, CEIC and CNPD. Additionally, it is also included a 
statement that the sponsor will only initiate the trial when every authorisations are 
gathered.  
c. declaration of site conditions – a statement that indicates that every departments 
of the hospital involved in the trial have the adequate conditions, namely the equipment, 
the facilities and the human resources required. This declaration is signed by the PI and 
by all the Head of departments involved.  
d. declaration of the recruitment’s modality – a document where the PI states how 
the patients that fulfil all the inclusion criteria will be identified, and that the recruitment will 
only be performed by the investigators.  
e. declaration of participant’s compensation – a statement signed by the PI referring 
that only the expenses incurred due study participation are reimbursed to the participants.  
f. investigational product circuit –defines who is responsible for perform the different 
tasks (the supply, the reception, the storage, the prescription, the preparation, the 
dispensing, the administration, the devolution and the destruction) related with the IMP. 
This document is discussed between the CRA and the Pharmacy.  
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g. declaration of conditions from the Pharmacy –the Head of the department states 
that the pharmaceutical department has the adequate conditions to perform all the 
activities related with the IMP.   
h.  PI Curriculum Vitae (CV) – A PI CV referring the PI’s experience in clinical trials, the 
professional experience, the GCP training and any other relevant information for the 
matter. 
 
Simultaneously, the financial contract is reviewed and negotiated by Blueclinical’s back-
office. This document defines the economic aspects, namely the direct and indirect costs 
of the study, the payment period and all conditions established between the parties. 
Moreover, it is also stated in this document, the confidential and publication policies. The 
research team members, the payment percentages, the recruitment goal and other 
relevant information are addressed to the back-office by the CRC.  
The submission process for observation studies has some differences. The observational 
studies are evaluated by the AB and by Ethics Committee at CHVNG/E –  Comissão de 
Ética para a Saúde (CES), and by the CNPD. In this case, any document related to 
pharmacy and IMP is not applicable.  
  
Figure 7 Approval process for clinical trials in Portugal. 
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INVESTIGATOR MEETING 
For most of the clinical trials and observational studies, an Investigator Meeting (IM) is 
organized by the clinical trial sponsor. All the investigators and site personnel from each 
site participating in the clinical study should be present. In this meeting is addressed 
information regarding the pharmacology of the IMP and also updated the clinical 
information of compound. Moreover, it is presented the study protocol, is explained the 
study design and other clinical trial procedures, and is provided training in therapeutic 
area, eCRF and other tools like the patient-reported outcomes (PROs) (42). These 
meetings are also an opportunity to contact with others clinical research team members, 
and to learn with their knowledge and experience.  
During my internship, I had the opportunity to attend in two IM, both for clinical trials in 
patients with lung cancer (the first one was performed in Barcelona, Spain and the second 
was performed in Frankfurt, Germany).  
SITE INITIATION VISIT  
The site initiation visit (SIV) is required to prepare and set up a research site to conduct 
the study. This visit occurs usually after all required approval from the competent 
authorities and the AB (figure 7). This meeting is scheduled according the availability of 
the research team, including the representative’s availability of each hospital department 
involved (41). Before the SIV, some pending issues for the trial initiation at site must be 
solved. Each member of the research team must complete all required trainings and must 
activate the accesses to the platforms – e.g. eCRF and IWRS. Moreover, CVs of research 
team and the signature of the financial disclosure must be obtained and filed. Some of 
these requirements are not applicable for observational studies.   
CRA or another sponsor representative is responsible for conducting the SIV. During this 
meeting, the following topics are presented:   
a. the study protocol: the objectives and the study design, the inclusion and exclusion 
criteria, the strategies and the targets of recruitment, the recruitment timelines and the 
study-specific procedures; 
b. the investigational product: the dispensing, the preparation, the administration and 
the unblinded procedures, if applicable;  
 30 
 
c. the laboratory procedures: the sample collection, the requirements for the 
processing and the shipping of biological samples to central laboratory, the supplies of 
central laboratory kits, the overview of the laboratory manual and the shipping materials;  
d. the safety reporting: the procedures to report and to record serious adverse events 
(SAEs) and adverse events;  
e. data collection: the eCRF and PRO, if applicable (41). 
In this visit, all research team members sign the delegation log and the training log. The 
delegation log is a document where “the investigator should maintain a list of appropriately 
qualified and trained persons to whom the investigator has delegated significant trial –
related duties” (43). The training log includes the people that have received training by 
attending to this meeting. If, for some reason, any element of the research team cannot be 
present at SIV, he/she will receive training by a member of the team who has been 
present in the initiation visit. 
After the SIV, in most cases, the site is ready to initiate recruitment strategies and to begin 
enrolling patients. This confirmation is sent by e-mail from the sponsor. In some 
particularly cases, this not occur due some pending issues, e.g. legal approvals missing, 
web portal account activation missing.  
 
5.2.2. CLINICAL TRIAL CONDUCTION ACTIVITIES 
RECRUITMENT PERIOD 
The expected number of patients to include in the study and the recruitment timeline is 
presented during the SIV. Once the recruitment period is opened, it is investigators’ 
responsibility to recruit patients that meet all the inclusion criteria, and none of the 
exclusion criteria for the study. However, the CRC can contribute to the patient 
recruitment.  
During my internship, I adopted two different strategies in order to identify potential 
patients, such as the analysis of clinical processes and the attendance in the consultation 
group. In the analysis of clinical processes, I read the clinical data of patients and checked 
the eligibility criteria of the study. After this review, the patient is flagged, and this 
information was addressed to the investigator. It is relevant highlight that, all the criteria 
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are then verified by the investigator. When a potential patient was identified during the 
consultation group, the eligibility criteria were analysed, according to the clinical data of 
the patient available. In these meetings, it also was emphasised the flowchart of the 
events and the essential aspects related to the treatment proposed to the investigator. 
This information was addressed to the patient during the medical consultation, where the 
informed consent form (ICF) was presented and the patient advised to take home the 
document, read it carefully and to identity doubts to be clarified.  
SCREENING 
The screening is a period of time (days or weeks) used to assess the patients’ compliance 
with the protocol criteria. First of all, the physician must clarify all doubts of the patients 
regarding the ICF and/or the study. If the patient agrees to participate and to sign the ICF, 
this information needs to be registered in medical records. It must be registered how the 
ICF was presented, must be detailed that all the doubts were clarified and that two copies 
of this document are signed. One copy of the ICF is given to the patient, and another is 
kept in the Investigator Site File (ISF).  If the patient was unable to sign the document, two 
independent witnesses or the legal representative can sign and can date the documents. 
Only after this, all screening procedures according to the protocol requirements can be 
performed and/or scheduled.  
The inclusion of the patient in screening of the study need to be registered in the IWRS or 
IVRS, according to the protocol procedures, by the CRC. These systems attribute a 
screening number to the patient.  
The next step is to schedule the exams, the laboratory analysis and other procedures 
required by protocol. It is crucial to ensure that the results of the exams and the laboratory 
results are available within timeline defined in the protocol to randomise the patient.  
RANDOMIZATION 
In another medical consultation, the investigator assesses the results of the exams and/or 
laboratory analysis, and checks the eligibility criteria worksheet with the inclusion and 
exclusion criteria. If the patient meets all inclusion criteria, and none of the exclusion 
criteria, the patient is randomised through the IVRS/IWRS. The randomisation is the 
allocation method of patient population into groups that will receive different interventions 
which may be test or control groups. The aim of this method is to avoid the bias, assuring 
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that subject populations are similar in all groups, to minimise systemic differences 
between groups that could affect the outcomes and to provide a powerful basis for 
statistical inference. If the patient does not meet the eligibility criteria, the subject is 
considered a screening failure, and this also need to be registered in the IVRS/IWRS (44).  
PATIENT VISITS 
Some activities related with the patients, namely scheduling, preparation and supporting 
the visits and/or other procedures are performed by the CRC. These visits and all the 
procedures required must be performed in accordance with the periodicity defined in the 
protocol.  
The analysis of the study flowchart is essential to schedule the procedures and to prepare 
the clinical visits. Usually, it is necessary to contact the patient a) to communicate date 
and time of blood tests and other procedures, e. g. computerised tomography 
electrocardiogram or blood tests, b) to remember the patient to bring to the site the 
unused study medication and the medication diaries and c) to alert the patient to be fasted 
for biological collection, if applicable.  
The preparation of the visits comprises the elaboration of a checklist in Microsoft Word 
document for each visit. This guide contains a list of all topics needed to record in clinical 
process of patient by the investigator, in order to fulfil the protocol. In this template, it is 
also provided the next date of patient visit and/or study procedures, e.g. blood samples 
collection, next treatment or computerised tomography. Additionally, sometimes it is also 
elaborated a guide with all procedures to be performed per protocol. With this 
methodology, the records are more accurate and complete. All members of the research 
team that will perform any procedure in the visit are informed with the adequate 
information by e-mail, phone or in person.   
During the patient visit, it is necessary an exceptional articulation between all team 
members to perform the procedures required per protocol. Besides the medical 
consultation with the investigator, the protocol may require the collection of biological 
samples, the dispensation of medication and/or other procedures e.g. perform a 12-lead 
electrocardiogram or a spirometry. When it is required collection of blood, urine or others 
biological samples, the laboratory kit provided by the sponsor needs to be available and 
the tubes identified with the subject number. This laboratory kit is delivered previously to 
the study nurse. After the collection, the biological samples, if applicable, are processed in 
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local laboratory and then, they are sent to central laboratory. All procedures are performed 
according to the information available in Laboratory Manual of each study. In this manual, 
it is also specified if the biological sample is sent in ambient temperature or frozen. The 
frozen biological samples are sent in a package with dry ice, which needs to be requested 
previously. The packaging and the sending of the samples through the courier are 
responsibility of the CRC.  
Regarding the drug dispensing, the IVRS/IWRS may be use to assign the medication. 
Two copies of the report of IVRS/IWRS drug dispensing are printed. In this report is 
presented the subject clinical trial identification, the treatment assigned and the batch 
number, if applicable. In addition to this report, the investigator also signs and dates the 
prescription form. Then, these two documents are delivered to the Pharmacy. If 
applicable, the return medication of the last period treatment is also delivered to allow the 
determination of compliance. The determination of treatment compliance is relevant to the 
results of the study.  
DATA ENTRY 
After each patient visit, source data is introduced in Case Report Forms (CRFs), which 
may be in paper or electronic. However, during my internship, I always worked with 
eCRFs. Source data is all information in original records and certified copies of original 
records of clinical findings, observations, or other activities in a clinical trial, and is 
necessary for the reconstruction and evaluation of the trial (45). This data should be: a) 
accurate, b) legible, c) contemporaneous, d) original, e) attributable, f) complete, g) 
consistent, h) enduring, and i) available when needed. Thus, the elaboration of a template 
guide to the patient visits helps to achieve some of these attributes (45). After patient visit, 
source date is organized in the patient file, and then introduced in each CRF page.  
During my internship, I performed data entry of many clinical trials and observational 
studies. Sometimes, some information was missing or was not totally clarified in patient’s 
records. In these cases, I took note, and then inquired the investigator to complete the 
patient’s records.  
When data entered does not pass in validation rules, the eCRF or the sponsor reviewers 
generate a query. A query requests to the investigator and/or CRC to review and/or to 
clarify the information introduced. The respond to queries must be done urgently in order 
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to ensure that results can be reported. First I always checked and reviewed the source 
data, and thereafter I modified data entered or clarified the information introduced. 
SAEs REPORTING 
SAE is any untoward medical occurrence that at any dose: 
 results in death, or  
 is life-threatening, or  
 requires inpatient hospitalization or prolongation of existing hospitalization, or  
 results in persistent or significant disability/incapacity, or  
 is a congenital anomaly /birth defect 
 is a medically important event.  
In the case of occurrence of a SAE in the course of the study, then Investigator or other 
site personnel must inform the sponsor representative within one day, i.e. immediately but 
no later than 24 hours of when he or she becomes aware of it. The initial report is 
completed by investigator with the information available, ensuring that the patient’s 
identity is protected. The following information is relevant for reporting a SAE: a) the date 
of onset and the end date, b) the causal relationship with the trial medication, c) the 
intensity (mild, moderate or severe) and d) the outcome of the event. Sometimes, the 
information available is incomplete within 24 hours. Thereafter, as soon as new 
information is available, a follow-up report needs to be sent. In the report should also be 
sent in attachment all examinations carried out, the laboratory results and the 
hospitalization reports, if applicable. All the information related with the SAE need also be 
entered within the same period of time in the appropriate forms of the eCRF (43) .  
MONITORING VISITS 
The main purpose of monitoring visits is to verify and to oversee the progress of the 
clinical trial and to ensure that it is being conducted, recorded and reported in accordance 
with the protocol, the GCP and the applicable regulatory requirements. More specific, the 
objectives are:  
a. to ensure the protection and well-being of human subjects;  
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b. to guarantee that reported trial is accurate, complete and verifiable from source 
documents;  
c. to verify the clinical trial compliance with protocol/amendments, GCP and regulatory 
requirements (41).  
Therefore, before each monitoring visit, the patient file(s) is/are reviewed, the missing data 
is introduced and other outstanding issues, related e.g. with queries, are resolved. The 
patient file(s), the subjects’ medical processes and the ISF need to be available during the 
monitoring visit. The investigator(s) and the CRC need also to have time to answer any 
doubts and to clarify any information. However, sometimes it is not possible to solve all 
the issues. After the visit, the monitor sends a follow-up letter, where it is described the 
unsolved issues. I always used this letter as guidance in order to solve the pending 
issues, as soon as possible.  
During this visits, the monitor can also provide training to any new element of the research 
team and/or regarding a new protocol amendment. Moreover, the monitor can also 
highlight any problematic question of the protocol.   
 
5.2.3.  CLINICAL TRIAL CLOSE-OUT ACTIVITIES 
CLOSE-OUT VISITS 
The close-out visit is only performed after the last patient had completed the scheduled 
visits defined per protocol. First, the sponsor defines the different timelines to complete 
the CRF, to solve queries, and when the database will be locked. A notification of the end 
of the study is sent to the investigation team. The data introduced in eCRF is reviewed, 
and I need to be with attention to CRF to solve, as soon as possible, all queries (41). 
Sometimes, this task involves the revision of source documents from the beginning of the 
clinical trial/observational study. Then, in the close-out visit, all the documents, including 
the ISF and the patient file are verified and any outstanding issues are resolved.  In the 
end of data revision, the PI can sign the CRF (41).  The PI must also be available during 
the close-out visit to sign and date all documents. These documents must be archived in 
order to be accessible in the future upon request, during an audit or an inspection. The 
essential documents of the clinical trials should be retained until at least 2 years after the 
last approval of a marketing application in an ICH region and until there are no pending or 
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contemplated marketing applications. However, the period can be longer according the 
agreement between the sponsor and the PI.  
All equipment and materials assigned to the hospital during the trial are returned during 
this period. Unused biological sample kits are destroyed.  
Regarding the observational studies, the close-out visit is very similar of a clinical trial.  
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6. DISCUSSION  
In this chapter, I will present my reflections regarding the internship and I will discuss if the 
learning goals have been achieved. In addition, I will also present the difficulties that I 
experienced and I will identify the strategies adopted to solve the problems.  
The internship was an opportunity to transpose the scientific and the theoretical 
knowledge acquired during the Master to the practice of the clinical research. This was a 
challenging and an exciting experience because represented a new period in my 
professional life. Moreover, during the internship I assumed the responsibility of being 
primary CRC in some therapeutic areas (oncology, hematology, nephrology, 
gastroenterology and vascular surgery). This contributed to the increase of my 
responsibilities at site, but also to have conscience of the importance of my work to 
improve the clinical research at CHVNG/E. Besides these therapeutic areas, I had the 
opportunity to conducting activities in other therapeutic areas. I also gathered experience 
in conduction clinical research activities in rheumatology, dermatology, internal medicine, 
pneumology and ophthalmology trials.   
I recognize that a previous knowledge about the clinical trials process accelerated my gain 
of autonomy to perform the CRC activities. However, at the beginning of the internship, I 
took time to learn the working procedures, the structure and the organization of the clinical 
research site. This information was essential in order to define the goals of my work, to 
prioritize my tasks and to adapt and to flexible my work methodology. Additionally, I 
understood that a progressive knowledge about the pathological aspects and the 
treatment guidelines of several diseases helped me in my activities/tasks. This knowledge 
helped me during my pre-screening activities, e.g. the analysis of the clinical patient files 
and attendance in the consultation group, and facilitated the communication with the 
investigators regarding the potential subjects to enrol in a clinical trial.  
At the beginning of my internship, I also needed the guide and the help of my colleagues 
to integrate me in the research teams and to perform the activities/tasks. I realized that 
the team work has a critical role to perform the clinical coordinator activities and to 
promote clinical research at site. The fact that the research team is constituted by several 
professionals with different ways of working and organisation is another relevant aspect to 
consider. Besides this, they need to conciliate the clinical investigation with the clinical 
practice.  Therefore, I needed to adapt me to their schedules, to understand their work 
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methodologies and met their expectations. A good relationship and an excellent 
communication flow with all team members were critical to facilitate my work. Many times, 
it was necessary the help of other elements of the research team to manage several 
subject visits occurring simultaneously in different departments. In order to manage these 
situations, previously I analysed the protocol and articulated with these elements how the 
patient visit would be managed and which procedures would be performed. I also ensured 
that all worksheets and guidelines developed were available in time. These documents 
supported the subject visits and contributed to the quality of data. 
I was always available to support any team member of the clinical research during his/her 
tasks. Moreover, I was always available to solve quickly any doubt or any pending issue, 
since I was the contact point between the research team, the monitor and all hospital 
departments involved in clinical research. During my internship, the progressive 
knowledge about the specific procedures of each clinical trial contributed to my ability to 
solve any new problem/doubt. For this, it was also very useful to understand the structure 
and the organization of the clinical research site, but also the identification of the role of 
each person in several departments.  
The clinical coordination activities were organized and planned timely, considering the 
priority of each task. All clinical visits were carefully scheduled and prepared, ensuring 
that all timelines and procedures were compliant with the protocol. Besides this, I also 
understand that it is relevance the conduction activities according to the ICH guidelines 
and other regulations. The patient data recorded during the clinical visit was maintained 
updated in the source documents. They are appropriately archived and organized in the 
patient file, which facilitated the introduction of the data into CRF and helped to support 
the monitoring visits.  
I established a personal contact and a good relationship with the patients. I realized the 
importance of demystification of the participation in a clinical study and the relevance of 
keeping a good flow of communication with them. During the screening visit, in some 
cases, I supported the investigator explication regarding the ICF and the procedures that 
would be performed during the trial. I also had an active participation during the patient 
visits. I was responsible to manage the procedures required by the protocol, to return the 
medication to the Pharmacy, and also to deliver it to the patient. However, sometimes 
conflicts situations emerged because the visits were too long. In these situations, I tried to 
identify the reason why it was taking so long, and explain it to the patient.  
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Another critical point, it is the collaboration with other elements outside of the hospital, 
such as the CRAs. The cooperation and the exchange of experience with the CRAs 
contributed to the gain of knowledge and competences to perform the clinical trials 
activities.   
Sometimes, I had some difficulties due to lack of experience to deal with the unexpected 
situations, namely failure of electronic systems, changes in deadlines, among others. 
However, during my internship I gained experience in management and resolution of 
these types of issues.  
In respect to my professional learning outcomes, I did not provide an equal contribution to 
all clinical trials coordination activities. I have gained more experience in performing the 
initiation and conduction activities, over the research site submission process and the 
close-out visits. The above-mentioned difference in the activities performed is related the 
fact that the submission process is conducted majority of the time by my colleague. 
Nevertheless, several times, I sent by email the explication of how perform the research 
site submission process and accompanied several times this task.  
Several times during the internship, I had the necessity of to perform a critical analysis of 
my work methodologies, and I identified several aspects to improve my work efficiency. 
The main goal of this analysis was to develop the proposed activities in an effectively and 
efficiently manner. To help this, I adopted several strategies, such as to register all 
important events (patient visits, SIVs, monitoring visits, close-out visits) in my planner, a 
“to do list” with the pending issues and a Microsoft Excel page with the protocol 
procedures that is necessary to schedule with the different vendors.  Furthermore, in a 
progressive way, I oriented the other elements of the research team to perform their 
activities in an autonomy way.  
Unfortunately, I did not cooperate in any audit or inspection. I consider that they are an 
opportunity of learning and improvement. I also would like to help the development a 
clinical trial from investigator initiative, since the beginning.  
During the internship I had the opportunity of training and developing skills and 
competences as CRC, in professional settings. Overall, I consider that my training 
objectives were achieved with success. Regarding the impact on my personal growth, the 
internship allowed me to acquire and to develop my interpersonal relationships and my 
teamwork, my critic spirit and my organization skills.  
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7. CONCLUSION 
The internship as CRC represented an enriching experience since it allowed me to 
transpose and to consolidate the knowledge acquired during the Master. Besides this, I 
developed skills and competences as CRC, I strengthened my professional skills and my 
interpersonal relationships in professional settings. Additionally, it gave me a clear 
perception of the critical role of the CRC as element of the research clinical team. The role 
of CRC has become increasingly demanding, with trials and the environment where they 
are conducted becoming more complex every year. This is even more relevant, 
considering that in Portugal, the main reasons of the low performance in clinical trials field 
are due organizational and logistic problems.  
During the internship, I had the opportunity to contact and to perform several activities 
according to the stages of the implementation and conduction of a clinical study (initiation, 
conduction and close out) in several therapeutic areas. In a progressive way, I gained 
experience and expertise in order to perform the above-mentioned activities in an 
autonomous way. At the same time, I developed several strategies to improve my work 
efficiency.  
The internship required a dynamic and enterprising attitude. Then, I felt that I adopted a 
more proactive and assertive attitude, in order to promote clinical research at CHVNG/E. 
Simultaneously, I improved my problems solving skills and learned that even in adverse 
situations, it is necessary to achieve a solution.  
My work was always performed in compliance with the protocol, the GCP, the ICH 
guidelines, and other relevant regulations. Moreover, in all situations, it was always 
considered the best interest and the welfare of the patient, and the quality of the clinical 
trials results.  
Thus, I consider that the learning objectives previously defined were achieved with 
success. In conclusion, the internship fulfilled its purpose because give me the opportunity 
to develop competences and skills as CRC.  
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